Futura Medical Share Discussion Threads

[lbo] 13/12/2022 08:03

So why aren’t Lombard buying it on the cheap!?



LOL



Lombard Odier will receive a total of 10,937,500 warrants to subscribe for further new Ordinary Shares at a price of 40 pence per share, exercisable until the fifth anniversary of their issue, in respect of its participation in the Subscription.

[broomrigg] 13/12/2022 08:01

BLUE start ;-)

[lbo] 13/12/2022 07:56

ROFLMAO

Deja vu yet again! The usual jam tomorrow end of year/pre fundraising announcement! It is impressive that they can keep pulling the same rabbit from the December hat and some are still mesmerised by the magic illusion!



A product that contemporary technology does not understand must establish that this magic, actually works. Proof is what separates an effect new to science from a swindle . . . . If a condition responds to treatment, then selling a placebo as if it had therapeutic effect directly injures the consumer



But will it be enough to get the next fundraising away? The last was at 47p! Why don’t Lombard just exercise their warrants at 40p and go over 30% and force a buyout of the company if its so cheap! LOL




All Futura have done with MED3000 is open the door for Reckitt to sell similar lubricants/arousal gels as medical device placebo treatments for ED. And report Med3000 to the ASA, FTC etc for being misleading if it doesn’t inform consumers that MED3000 itself has no proven effect in ED beyond a placebo. As it has no proven efficacy in an adequate placebo controlled study or even against any standard cooling lubricant/arousal gels in an ED study.



‘You are the active ingredient’

Even the analysis on market forecasts knows Reckitt who is the market leader in lubricants will be only one to gain from marketing lubricants as placebo treatments for Erectile Dysfunction




Reckitt Benckiser was the defined leader and the ultimate four Personal lubricant vendors with leading brands such as Durex Play and K-Y Jelly.

KEY GROWTH FACTORS

Increasing prevalence of erectile dysfunction

9 Market Growth Enablers
9.1 Increasing Prevalence of Erectile Dysfunction

[sos100] 13/12/2022 07:43

excellant news..

LBO posting here like a madman was the best signal ever 👏

[j777j] 13/12/2022 07:42

Futura filed an application for Marketing Authorization as a De Novo Medical Device in October 2022 , presenting the case that MED3000 is an effective clinically proven treatment for ED with a 10-minute onset of action and a favourable benefit versus risk profile ideally suited for OTC classification.The FDA has now confirmed that the dossier is under formal review and has indicated that the dossier has successfully passed the initial technical screening. Based on the FDA's published target review period guidelines, granting of marketing authorisation remains on track to be achieved by the end of Q1 2023, in line with previously announced timelines.

[j777j] 13/12/2022 07:40

To the moonCongratulations to all holders

[lbo] 13/12/2022 07:16

LOL

The jam tomorrow always fails to materialise. What did ever happen to Kabey Pharmaceuticals? They vanished off the face of the planet after CSD500 failed in MENA. Which is odd since at the time kaney were announced as Futuras partner they were said be a ‘big group’ and ‘well established’


05 Jan 2017 N+1 Singer - Futura Medical -

CSD500 launch in Saudi Arabia N+1 Singer Dr Jens Lindqvist 3 pages

The first CSD500 launch in the UAE region is a positive development, and we are looking forward to further launches by Kabey Pharmaceuticals (Futuras MENA partner) in 2017.

[broomrigg] 13/12/2022 07:07

Excellent positive RNS this morning.

11th consecutive BLUE day today?!

:-)

[truant2tb1] 12/12/2022 19:32

I'm struggling to think of a reason why this share isn't an aggressive SELL, looks like a spike ahead of a placing

The idea FUM have a commercial product when you can get a viagra substitute for 71p is for the fairies

[lbo] 12/12/2022 19:28

All Futura have done with MED is open the door for Reckitt to sell lubricants/arousal gels as medical device placebo treatments for ED. And report Med3000 to the ASA, FTC etc for being misleading if it doesn’t inform consumers that Med3000 itself has no proven effect in ED beyond a placebo. As it has no proven efficacy in a placebo controlled study or even against any standard cooling lubricant/arousal gels.



‘You are the active ingredient’

Even the analysis on market forecasts knows Reckitt who is the market leader in lubricants will be only one to gain from marketing lubricants as placebo treatments for Erectile Dysfunction




Reckitt Benckiser was the defined leader and the ultimate four Personal lubricant vendors with leading brands such as Durex Play and K-Y Jelly.

KEY GROWTH FACTORS

Increasing prevalence of erectile dysfunction

9 Market Growth Enablers
9.1 Increasing Prevalence of Erectile Dysfunction

[brigand] 12/12/2022 19:08

Carry on with your BREAKING NEWS !! Broomrigg .....

It's a welcome change in a sea of filtered comments...

:-)

[petroc] 12/12/2022 18:06

Stock bashing has become very common in the digital world and often occurs on online trading platforms. Sophisticated technology makes it easy for bashers to remain anonymous. As such, it can be difficult to track, identify, and stop bashers in their tracks.

As the internet makes participation in the stock market more accessible to more people, new investors emerging in the market are especially vulnerable to the tactics of stock bashers, and many investor boards exist to attempt to track perpetrators.

Though notoriously difficult to track, some bashers have been identified and prosecuted. From time to time, confessional essays about the tactics of bashers emerge online, although these essays are typically also either anonymous or pseudonymous. Many investors speculate this type of behavior tends to follow certain patterns, including a tendency for bashers to only bash stocks which are generally trending upwards and showing potential.

Having said that, financial regulators constantly monitor the markets for what they call bad actors or stock bashers. According to the Financial Industry Regulatory Authority (FINRA), investors may find it difficult to get information about these securities and any tidbits they may find can lead them to act even if it's misinformation. That's why FINRA warned investment firms and broker-dealers to put controls in place that would raise red flags on any suspicious activity

[lbo] 12/12/2022 17:39

https://www.ftc.gov/sites/default/files/documents/cases/2008/01/080103qtrayseventhcircuitappealruling.pdfSelling brass as gold harms consumers independent of any effect on pain. Since the placebo effect can be obtained from sugar pills, charging $200 for a device that is repre- sented as a miracle cure but works no better than a dummy pill is a form of fraud. Thats not all. A placebo is necessary when scientists are searching for the marginal effect of a new drug or device, but once the study is over a reputable professional will recommend whatever works best.Medicine aims to do better than the placebo effect, which any medieval physician could achieve by draining off a little of the patients blood. If no one knows how to cure or ameliorate a given condition, then a placebo is the best thing going. Far better a placebo that causes no harm (the Q-Ray Ionized Bracelet is inert) than the sort of nostrums peddled from the back of a wagon 100 years ago and based on alcohol, opium, and wormwood. But if a condition responds to treatment, then selling a placebo as if it had therapeutic effect directly injures the con- sumer. See Kraft, Inc. v. FTC, 970 F.2d 311, 314 (7th Cir. 1992) (a statement violates the FTC Act ‘if it is likely to mislead consumers, acting reasonably under the cir- cumstances, in a material respecthttps://academic.oup.com/book/6511/chapter-abstract/150416159?redirectedFrom=fulltext&login=falseBias and FraudThere are numerous biases in medical research that render evidence from such research systematically misleading. Some of these biases are exacerbated by conflicts of interest, including fantastic financial incentives. The most important biases in medical research include confirmation bias, design bias, analysis bias, and publication bias. Arguably, some forms of bias, such as publication bias, should be considered as fraud. The pervasiveness of bias in medical research justifies one of the premises of the master argument for medical nihilism. Medical research is malleable due to the many biases, and such malleability allows for the production of evidence that suggests medical interventions are effective, whether or not they are in fact effective.https://help.magicapp.org/knowledgebase/articles/294932-how-to-rate-risk-of-bias-in-randomized-controlledWhat method-issues to consider when assessing Risk of BiasConcealment of randomizationThose enrolling patients are aware of the group (or period in a cross-over trial) to which the next enrolled patient will be allocated (major problem inpseudo or quasi randomized trials with allocation by day of week, birth date, chart number etc.)BlindingPatient, caregivers, those recording outcomes, those adjudicating outcomes, or data analysts are aware of the arm to which patients are allocated (or the medication currently being received in a cross-over trial)

[lbo] 12/12/2022 17:30

The Placebo Effect: How Important Is It in ED Treatment?




Placebo Effect Found to Improve Erectile Dysfunction



Men with erectile dysfunction (ED) who were in the placebo arm of clinical trials of phosphodiesterase 5 inhibitors (PDE5Is) had significant improvement in erectile function, with a more pronounced effect among men with posttraumatic stress disorder (PTSD) according to a recently published systematic review and meta-analysis.